Flamma Group acquires additional API site in Italy
The company wil acquire a third API manufacturing site in Lecco, Italy as of April this year
Chignolo D’Isola, Bergamo, Italy – March 16, 2022 – The Flamma Group (“Flamma”), a global, fully integrated company producing and commercialising small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organisation (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, announced that it will acquire a third API manufacturing site in Italy as of April 2022.
Flamma reached an agreement earlier this year with Teva Group for acquiring Sicor Bulciago site located in Lecco, Italy, only 30 km from Flamma’s headquarters. It has a long history of established cGMP manufacturing of pharmaceutical materials including APIs. It has more than 600 cubic meters of manufacturing capacity and has been previously inspected by the FDA, the Italian Ministry of Health (AIFA), the Brazilian Health Regulatory Agency (ANVISA) and has been accredited by the PDMA (Japan).
This acquisition strengthens and expands Flamma’s manufacturing services as a fully integrated CDMO that is privately held and family run since 1950. The ability to integrate Bulciago into the Flamma Group will be enhanced by the proximity of the site as well as the familiarity of numerous current Flamma employees who previously worked at the site.
Dr. Gianpaolo Negrisoli, Chief Executive Officer of Flamma, noted, “We are extremely happy to bring the Bulciago site into the Flamma Group of companies. This allows us to rapidly enhance our CMC offerings to our customers by providing further flexibility between sites. Having the ability to produce more generic APIs in Italy is in line with the European Pharmaceutical strategy aiming to reshore by having a more robust and resilient supply chain in the pharmaceutical sector that is not totally dependent on Asia.”
Negrisoli adds, “For this reason, we could not allow this factory, so important, with a history of more than 50 years and a production and technological tradition of great value, to disappear. We are very proud to be able to guide its rebirth towards very significant production goals.”
“With Bulciago, Flamma adds 600 cubic meters of available manufacturing capacity bringing our total capacity in Italy to over 900 cubic meters. This goes along with the soon to be 600 cubic meters of manufacturing capacity in China as we begin expansion of Flamma Honkai this year”, added Negrisoli.
Flamma has been busy over the past few years with the addition of Flamma USA in Malvern, PA just outside Philadelphia to handle early stage small molecule projects. The soon to be completed R&D expansion at Chignolo that will quadruple its R&D space there and allow for not only more R&D capabilities but allows for additional analytical resources in the building that was shared between the two groups. Flamma will invest over €150 million ($167M) over the next three years for increasing capacity and the addition of new technologies across its sites in Italy, China and the USA.
“This is an exciting time at Flamma as we continue to grow to over 1,500 cubic meters of total manufacturing capacity yet still maintain our roots as a family owned and run company focused on developing long term relationships with customers that are looking for a true partner moving forward in their drug development CMC needs,” concludes Negrisoli.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance